Meantime, Avast Software saw the dark clouds gathering for cloud companies and withdrew its IPO altogether. Avast is a popular security software and its planned pricing was aiming for a valuation of more than $800 million. It produced only revenues of $91 million last year and net income of $27 million.
It seems the cloud companies have to go back to the drawing board for their price valuations. Take a lesson from the pharma companies that have gone public lately. Price low and then you have somewhere to go. The market will perceive your deal as a bargain.
Hyperion Therapeutics (HPTX - Get Report) priced its stock at $10 on July 26, below its planned range of $11-$13. The stock is already in positive territory. Supernus Pharmaceuticals (SUPN - Get Report) priced at $5 and the stock is up 157%. It was originally looking at a range of $12-$14.
Also, what if we change the way we look at LegalZoom? Instead of thinking of it as tech offering, let's think of it as a consumer service company, like Kayak (KYAK). On Kayak consumers walk away with something in their hand -- an airline ticket. On LegalZoom they walk away with a document like a will. Kayak is up 29%.So let's price it like a pharma and call it a consumer service company. That approach might set LegalZoom up for a successful offering. Unless they get creative, digital companies going public in the post-Facebook era will be fighting against the unforgiving forces of marketplace. -- Written by Debra Borchardt in New York.
>To contact the writer of this article, click here: Debra Borchardt. >To follow the writer on Twitter, go to http://twitter.com/wallandbroad. >To submit a news tip, send an email to: firstname.lastname@example.org.